A carregar...
A phase II evaluation of Irofulven (IND#55804, NSC#683863) as second-line treatment of recurrent or persistent intermediately platinum-sensitive ovarian or primary peritoneal cancer: A Gynecologic Oncology Group trial
This multi-center phase II trial was conducted by the Gynecologic Oncology Group to evaluate the activity and safety of irofulven in patients with recurrent epithelial ovarian cancer. Eligible patients had documented recurrent ovarian cancer 6-12 months after receiving a front-line platinum-based re...
Na minha lista:
| Main Authors: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3079178/ https://ncbi.nlm.nih.gov/pubmed/21495215 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|